Amarin

Yahoo Finance • 22 days ago

European Equities Traded in the US as American Depositary Receipts Start Week Sharply Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were sharply lower late Tuesday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 24 days ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and on cellular stress and inf... Full story

Yahoo Finance • 25 days ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE... Full story

Yahoo Finance • last month

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid,... Full story

Yahoo Finance • last month

Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable

Amarin Corporation, with a market capitalization of $323.69 million, reported its Q2 2025 earnings, revealing a notable revenue beat with $72.7 million against a forecast of $42.55 million, marking a 70.95% surprise. Despite this, the comp... Full story

Yahoo Finance • 2 months ago

Amarin Reports Second Quarter 2025 Financial Results

-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 Financial Performanc... Full story

Yahoo Finance • 2 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to... Full story

Yahoo Finance • 3 months ago

Amarin Grants Recordati Exclusive Rights To Commercialize VAZKEPA Across 59 European Countries

(RTTNews) - Amarin Corporation (AMRN) has entered a long-term exclusive license and supply agreement with Italian pharmaceutical firm Recordati S.p.A. to commercialize VAZKEPA (icosapent ethyl) in 59 European countries. The deal, aimed at... Full story

Yahoo Finance • 3 months ago

Amarin inks licensing deal with Recordati for lead drug Vazkepa

[Collaboration concept in word tag cloud] rafal_olechowski Amarin Corporation (NASDAQ:AMRN [https://seekingalpha.com/symbol/AMRN]) traded ~7% higher in the premarket on Tuesday after the company announced an exclusive license and supply a... Full story

Yahoo Finance • 3 months ago

Amarin licenses VAZKEPA to Recordati in 59 European countries

DUBLIN/BRIDGEWATER - Amarin Corporation (NASDAQ:AMRN), which has seen its stock surge nearly 38% over the past six months according to InvestingPro data, announced Tuesday it has entered into an exclusive long-term license and supply agree... Full story

Yahoo Finance • 6 months ago

Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors

DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as... Full story

Yahoo Finance • 6 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of... Full story

Yahoo Finance • 6 months ago

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced its intent to effect a ratio change on its American Depositary Shares (“ADS”) from one (1) ADS representing one (1) o... Full story

Yahoo Finance • 7 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipoprote... Full story

Yahoo Finance • 7 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to... Full story

Yahoo Finance • 2 years ago

15 Best Shareholder Activism Law Firms

In this article, we discuss the 15 Best Shareholder Activism Law Firms. If you would like to discuss our detailed discussion and analysis of the shareholder activism space as of 2024, you can skip it and go directly to 5 Best Shareholder A... Full story

Yahoo Finance • 2 years ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Amarin Corporation plc DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president... Full story

Yahoo Finance • 2 years ago

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease -- -- Findings Continue to Reinforce the... Full story

Yahoo Finance • 2 years ago

Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript November 1, 2023 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.02. Operator: Welcome to Amarin Corporation'... Full story

Yahoo Finance • 2 years ago

Amarin Reports Third Quarter 2023 Financial Results

-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position... Full story